Skip to main content

Year: 2023

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023

November 1, 2023Announcement no. 18 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results and business updates for the third quarter and nine months of fiscal 2023. Recent HighlightsFor the first nine months ending September 30, 2023:Total revenue of DKK 24.4 million / USD 3.5 million, a 20% increase over the prior year Total NGAL revenue of 15.2 million / USD 2.2 million, a 57% increase over the prior year Adjusted EBITDA of DKK (41.2) million / USD (6.0) million Cash and cash equivalents of DKK 69.9 million / USD 9.9 million as of September 30, 2023 (DKK 98.9 million / USD 13.0 million as of September 30, 2022)For...

Continue reading

Aspo Group Interim Financial Report, January 1 to September 30, 2023: Aspo’s Q3 results improved considerably from Q2, yet not reaching previous year’s record level

Aspo Plc Interim financial report               November 1, 2023, at 9:30 am Aspo Group Interim Financial Report, January 1 to September 30, 2023 Aspo’s Q3 results improved considerably from Q2, yet not reaching previous year’s record level Figures from the corresponding period in 2022 are presented in brackets. From the beginning of year 2023, Aspo established a new segment structure and the figures for the comparative periods have been restated. July–September 2023Continuing operationsNet sales from continuing operations decreased to EUR 130.0 (142.8) million. Comparable operating from continuing operations profit was EUR 7.4 (12.4) million, and the comparable operating profit rate of continuing operations was 5.7% (8.7%). Comparable operating profit of ESL Shipping was EUR 4.0 (9.8) million, Telko EUR 3.1 (3.1) million, and Leipurin...

Continue reading

Sydbank’s Interim Report – Q1-Q3 2023

Company Announcement No 36/20231 November 2023 Sydbank’s Interim Report – Q1-Q3 2023 Q1-Q3 2023 – highlightsProfit for the period of DKK 2,409m equals a return on equity of 23.2% p.a. after tax Core income of DKK 5,227m is 42% higher compared to the same period in 2022 Trading income of DKK 240m is 36% higher compared to the same period in 2022 Costs (core earnings) of DKK 2,335m against DKK 2,288m in the same period in 2022 Core earnings before impairment of DKK 3,132m are 98% higher compared to the same period in 2022 Impairment charges for loans and advances etc represent an income of DKK 21m Bank loans and advances have gone down by DKK 1.8bn, equal to a decrease of 2% compared to year-end 2022 The CET1 ratio stands at 18.5%, equal to an increase of 1.2pp compared to year-end 2022CEO Karen Frøsig comments on the result:It is...

Continue reading

Financial results for Q1-Q3 2023

Company announcement no. 64 Net profit of DKK 1,871 million and return on equity of 20.8% The financial statements for the first nine months of 2023 show a highly satisfactory net profit of DKK 1,871 million and a return on equity of 20.8%. As was the case in the preceding quarters, the profit was to a large extent driven by higher net interest income resulting from the rising level of interest rates, whereas a lower level of activity in general resulted in lower net fee income. Meanwhile, owing to buoyant financial markets value adjustments of the Bank’s bond portfolio also made a fair-sized contribution to performance. Lastly, we were pleased to see sustained robust credit quality both among retail and business customers, which resulted in a DKK 29 million positive profit impact from impairment charges – despite the fact that...

Continue reading

32/2023 Green Hydrogen Systems – Trading statement Q3 2023

Company announcement 32/2023 Green Hydrogen Systems – Trading statement Q3 2023 Business highlightsIn Q3 2023, an electrolyser unit was revenue recognised and delivered to the Swiss customer Gaznat for green methane productionFollowing that, in October 2023, additional electrolysers have been factory acceptance tested, and deliveredSupply chain challenges for certain components impacted deliveries in Q3 2023 but are gradually resolved illustrated by the customer deliveries in October 2023Green Hydrogen Systems sees a larger risk of not realising the revenue guidance for 2023 due to a concentration of A-Series factory acceptance tests, deliveries and thereby revenue recognition in the last two months of 2023The X-Series prototype test and validation progresses toward high-pressure hydrogen production at the GreenLab test site....

Continue reading

Wolters Kluwer 2023 Nine-Month Trading Update

Wolters Kluwer 2023 Nine-Month Trading Update Alphen aan den Rijn, November 1, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today releases its scheduled 2023 nine-month trading update. HighlightsGuidance for 2023 reiterated. Nine-month revenues up 4% in constant currencies and up 5% organically.Recurring revenues (82% of total revenues) up 7% organically; non-recurring revenues down 2%. Digital & services revenues (94% of total) up 6% organically; print down 7%. Expert solutions revenues (58% of total) up 7% organically.Nine-month adjusted operating profit down 2% in constant currencies.Adjusted operating profit margin 26.1%, down 150 basis points, as expected. We continue to expect an increase in the full-year 2023 adjusted operating profit margin.Nine-month adjusted...

Continue reading

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential for additional milestones, plus tiered royaltiesNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agreement”), (ii) an investment agreement relating to an initial equity investment of $80M, and (iii) a memorandum of understanding (the “MOU”) relating to an additional equity investment of $140M, with AstraZeneca (LSE/STO/Nasdaq: AZN). The Collaboration Agreement aims to accelerate the development of next generation...

Continue reading

Spexis Announces Changes to the Executive Committee

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023. Martin Jakobovic, currently Head of Finance, will succeed Hernan Levett as interim Chief Financial Officer joining the Executive Committee on December 1, 2023. Additionally, Muriel Fleming, currently Head of Human Resources, will assume additional responsibilities related to administration and facilities, as well as joining...

Continue reading

Stellantis Announces Leadership Adjustments to Support New Strategic Activities in China

Stellantis Announces Leadership Adjustments to Support New Strategic Activities in China AMSTERDAM, November 1, 2023 – Effective today, Grégoire Olivier will take the responsibility of a newly created ‘liaison office’ to Leapmotor, reporting to Stellantis CEO Carlos Tavares. He will also serve as a board member of Leapmotor. Grégoire will ensure the dynamic execution of this new strategic partnership, including the creation of the sales joint venture and the coordination with Leapmotor on the use of Stellantis distribution and sales assets, to name a few. Doug Ostermann will be appointed Chief Operating Officer of China, reporting to Carlos Tavares, replacing Grégoire. Doug will also serve as a board member of Leapmotor. Doug has acquired a strong knowledge of Stellantis’ operations, and of the challenges of growing the business in the...

Continue reading

KH Group Plc’s Business Review January–September 2023: Profitable business in a challenging market

KH Group Plc Stock Exchange Release 1 November 2023 at 8:00 am EET KH Group Plc’s Business Review January–September 2023 Profitable business in a challenging market This is the summary of the Business Review for January–September 2023. The complete Review is attached to this release and is also available on the company’s website at www.khgroup.com. First quarter as a conglomerate Based on the change in strategy announced on 15 December 2022, Sievi Capital Plc transformed its operations from a private equity investment company into a conglomerate on 4 May 2023 by a decision of the Annual General Meeting. In connection with this, the company’s name was changed to KH Group Plc. The trading code of the share was previously SIEVI and was changed to KHG as a result of the change of the trade name on 10 May 2023. KH Group’s strategy will no longer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.